Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of MG2512 Injection in Participants With Advanced Solid Tumors

NCT07348653 is registered in ClinicalTrials.gov with Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07348653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of MG2512 Injection in Participants With Advanced Solid Tumors
Lead sponsor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 18, 2026
Completion date
December 31, 2027
Enrollment
116 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor